Brief: Acticor Biotech SA Annnounces Initiation Of Patient Enrollment In Green Phase 2/3 Study In Stroke
09/01/2023 17:05
Jan 9 (Reuters) - Acticor Biotech SA ALACT.PA :
* ACTICOR BIOTECH SA - INITIATION OF PATIENT ENROLLMENT IN
GREEN
PHASE 2/3 STUDY IN STROKE
Source text for Eikon: ID:nBw9Wk4Nza
Further company coverage: ALACT.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acticor Biotech SA
See all newsBrief: Acticor Biotech Announces Extension Of Call For Tenders
Brief: Acticor Biotech/Glenzocimab: Analysis Of Primary And Secondary Endpoints Of Phase 2/3 Actisave Showed No Improved Efficacy
Brief: Acticor Biotech Launches Capital Increase Of Minimum Of EUR 7 Mln
Brief: Acticor Biotech Announce First Patient In Liberate Clinical Trial With University Of Birmingham
Brief: Acticor Biotech Says Clinical Trial In Patients With AIS Showed Favorable Safety Profile Of Glenzocimab